Epimède
Epimède SA is a venture capital firm located in Liège, Belgium, established in 2015. The firm specializes in providing early-stage and growth capital investments to small and medium-sized enterprises, particularly those in the technology sector. Its investment focus includes life sciences, such as biology and biotechnology, as well as engineering services, medtech, cleantech, and corporate services. Epimède typically invests between €1 million and €7 million in companies that have fewer than 500 employees, net capital assets not exceeding €75 million, and are not predominantly owned by non-SMEs. The firm aims to support companies with growth potential and takes an active role in their governance by participating in the Board of Directors and influencing key strategic decisions. With a strategic exit plan spanning three to five years, Epimède is dedicated to fostering the development of innovative businesses primarily based in Wallonia.
Top Stages
5 past transactions
ImCyse
Series B in 2021
Imcyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, specializing in innovative immunotherapeutic solutions aimed at treating severe chronic autoimmune diseases. Founded in 2010, Imcyse is pioneering a unique technology platform that employs Imotopes™, specifically modified peptides that target immune cells responsible for organ damage. This approach facilitates the generation of cytolytic CD4 T-cells, which selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, thereby addressing diseases with limited treatment options. The company has shown proof of concept across various indications and has completed its initial clinical trial for type 1 diabetes, yielding promising outcomes. In addition to type 1 diabetes, Imcyse is actively developing a pipeline of therapies for multiple autoimmune diseases, aiming to provide effective treatment while preserving overall immune defense.
Endo Tools Therapeutics
Series D in 2021
Endo Tools Therapeutics S.A., established in 2008 and based in Gosselies, Belgium, is a medical device company focused on creating innovative devices for gastroenterologists. The company develops therapeutic devices that enhance interventional gastroenterology, including a triangulation platform known as ENDOMINA. This open platform enables gastroenterologists to perform a variety of therapeutic procedures more effectively. Endo Tools Therapeutics is also working on a catheter designed to provide additional therapeutic channels and enhanced maneuverability during interventions. The company's products aim to improve treatment options for conditions such as obesity, digestive tract tumors, and diabetes by facilitating flexible endoscopic suturing and tissue apposition, thereby enabling more efficient surgical endoscopy.
Endo Tools Therapeutics
Series C in 2019
Endo Tools Therapeutics S.A., established in 2008 and based in Gosselies, Belgium, is a medical device company focused on creating innovative devices for gastroenterologists. The company develops therapeutic devices that enhance interventional gastroenterology, including a triangulation platform known as ENDOMINA. This open platform enables gastroenterologists to perform a variety of therapeutic procedures more effectively. Endo Tools Therapeutics is also working on a catheter designed to provide additional therapeutic channels and enhanced maneuverability during interventions. The company's products aim to improve treatment options for conditions such as obesity, digestive tract tumors, and diabetes by facilitating flexible endoscopic suturing and tissue apposition, thereby enabling more efficient surgical endoscopy.
Ncardia
Series B in 2017
Ncardia is a biotechnology company focused on expediting the drug discovery and development process. Utilizing human induced pluripotent stem cell (hiPSC) technology, Ncardia develops predictive human cellular assay systems that facilitate safety and efficacy testing of drug candidates. The company's innovations enhance cardiovascular and neural drug screening, allowing researchers and drug discovery firms to incorporate predictive human disease biology into their processes. Through its advanced technologies, Ncardia aims to accelerate the overall drug discovery timeline, ultimately improving the efficiency and effectiveness of bringing new therapeutics to market.
Diagenode
Venture Round in 2016
Diagenode is an international life sciences company established in 2003 in Liège, Belgium, with a presence in Sparta, New Jersey, and a sales office in the United Kingdom. The company specializes in developing and commercializing advanced instruments and reagent systems for life science research and molecular diagnostics. Diagenode offers a technology platform that includes Bioruptor shearing and IP-Star automation instruments, along with reagent kits and quality antibodies. These products are designed to enhance workflows in epigenetics research, biological sample preparation, and diagnostic assays, serving a diverse clientele that includes prominent epigenetics researchers, academic institutions, genome centers, core laboratories, and pharmaceutical and biotechnology companies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.